Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 19/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8231872 | 0.91 | BACE1 (0.45) | BACE1BACE2PRMT5WDR77APP | |
| SCHEMBL8241158 | 0.89 | BACE1 (0.43) | BACE1BACE2PRMT5WDR77APP | |
| SCHEMBL8237064 | 0.71 | BACE1 (0.45) | BACE1BACE2PRMT5WDR77APP | |
| SCHEMBL8239579 | 0.71 | BACE1 (0.46) | BACE1BACE2CTSD | |
| SCHEMBL8237872 | 0.68 | BACE1 (0.34) | BACE1BACE2PRMT5WDR77CTSD | |
| SCHEMBL4528649 | 0.68 | BACE1 (0.57) | BACE1BACE2APPCTSD | |
| SCHEMBL4805777 | 0.68 | BACE1 (0.73) | BACE1BACE2CTSD | |
| Hydrochloric Acid SCHEMBL4532172 | 0.67 | BACE1 (0.71) | BACE1BACE2CTSD | |
| SCHEMBL8233330 | 0.66 | — | — | |
| SCHEMBL4519554 | 0.65 | BACE1 (0.55) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007058602-A2 | NOVEL 2-AMINO-IMIDAZOLE-4-ONE COMPOUNDS AND THEIR USE IN THE MANUFACTURE OF A MEDICAMENT TO BE USED IN THE TREATMENT OF COGNITIVE IMPAIRMENT, ALZHEIMER’S DISEASE, NEURODEGENERATION AND DEMENTIA. | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |